Abstract or die: Why AI enterprises can't afford rigid vector stacks

Enterprises adopting AI cannot afford to be slowed by database lock-in. As the vector ecosystem evolves, the winners will be ...
Yahoo Finance

Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?

Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.2% higher at $5.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Nasdaq

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...
eLife

A recursive pathway for isoleucine biosynthesis arises from enzyme promiscuity

The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark ...
pharmaphorum

AI biotechs Exscientia and Recursion agree $688m merger

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...